We are live on ! Find out more
MB

MPM BioImpact Portfolio holdings

AUM $1.64B
1-Year Est. Return 245.64%
This Fund
S&P 500
This Quarter Est. Return
+8.2%
1 Year Est. Return
+245.64%
3 Year Est. Return
+550.3%
5 Year Est. Return
+647.56%
10 Year Est. Return
–
AUM
$667M
AUM Growth
+$23.1M
Cap. Flow
+$3.29M
Cap. Flow %
0.49%
Top 10 Hldgs %
55.8%
Holding
54
New
10
Increased
20
Reduced
7
Closed
11

Top Buys

Rank Stock Value
1
RNAM
Avidity Biosciences
RNAM
+$24.5M
2
RCKT icon
Rocket Pharmaceuticals
RCKT
+$21.8M
3
TWST icon
Twist Bioscience
TWST
+$14M
4
JANX icon
Janux Therapeutics
JANX
+$7.44M
5
AQST icon
Aquestive Therapeutics
AQST
+$6.99M

Top Sells

Rank Stock Value
1
ALKS icon
Alkermes
ALKS
+$13.4M
2
MORF
Morphic Holding, Inc. Common Stock
MORF
+$12.6M
3
AVDL
Avadel Pharmaceuticals
AVDL
+$11M
4
XERS icon
Xeris Biopharma Holdings
XERS
+$10.9M
5
AXSM icon
Axsome Therapeutics
AXSM
+$10.7M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CGEM icon
1
Cullinan Oncology
CGEM
$1.4B
$128M 19.21%
7,648,268
– –
INSM icon
2
Insmed
INSM
$25.9B
$44.9M 6.74%
615,391
– –
OLMA icon
3
Olema Pharmaceuticals
OLMA
$899M
$32M 4.8%
2,680,596
+25,729
+1% +$329K
RNAM
4
DELISTED
Avidity Biosciences
RNAM
$31.6M 4.75%
688,975
+563,975
+451% +$24.5M
CRNX icon
5
Crinetics Pharmaceuticals
CRNX
$9B
$26.9M 4.03%
525,845
-31,339
-6% -$1.62M
EWTX icon
6
Edgewise Therapeutics
EWTX
$4.64B
$24.5M 3.67%
917,166
+176,505
+24% +$3.51M
IOVA icon
7
Iovance Biotherapeutics
IOVA
$3.63B
$22.6M 3.39%
2,406,714
+40,000
+2% +$379K
NTRA icon
8
Natera
NTRA
$47B
$22.5M 3.37%
177,099
+2,288
+1% +$263K
RCKT icon
9
Rocket Pharmaceuticals
RCKT
$424M
$19.7M 2.95%
+1,066,373
New +$21.8M
MIRM icon
10
Mirum Pharmaceuticals
MIRM
$5.94B
$19.2M 2.88%
492,723
+154
+0% +$6.14K
RARE icon
11
Ultragenyx Pharmaceutical
RARE
$2.52B
$18.3M 2.75%
329,733
-50,819
-13% -$2.59M
ITOS
12
DELISTED
iTeos Therapeutics
ITOS
$17.8M 2.67%
1,745,943
– –
MLTX icon
13
MoonLake Immunotherapeutics
MLTX
$1.28B
$17.6M 2.64%
349,063
+5,828
+2% +$273K
LNTH icon
14
Lantheus
LNTH
$6.58B
$16.5M 2.47%
150,182
+182
+0.1% +$18.9K
MDGL icon
15
Madrigal Pharmaceuticals
MDGL
$12.3B
$15.4M 2.3%
72,395
+1,210
+2% +$310K
IRON icon
16
Disc Medicine
IRON
$3.07B
$15.3M 2.3%
311,761
+6,103
+2% +$287K
RLAY icon
17
Relay Therapeutics
RLAY
$4.11B
$14.4M 2.16%
2,033,041
+758,582
+60% +$5.67M
TWST icon
18
Twist Bioscience
TWST
$8.87B
$13.3M 2%
+294,930
New +$14M
RVMD icon
19
Revolution Medicines
RVMD
$44.6B
$13.2M 1.98%
291,391
+1,995
+0.7% +$86.9K
GH icon
20
Guardant Health
GH
$21.7B
$11.5M 1.72%
499,170
-830
-0.2% -$23.5K
AKRO
21
DELISTED
Akero Therapeutics
AKRO
$11.3M 1.69%
392,544
+6,554
+2% +$171K
KALV
22
DELISTED
KalVista Pharmaceuticals
KALV
$10.4M 1.56%
896,915
+14,978
+2% +$188K
CMPX icon
23
Compass Therapeutics
CMPX
$432M
$10.4M 1.56%
5,641,894
+636,808
+13% +$794K
RNAC icon
24
Cartesian Therapeutics
RNAC
$290M
$10.1M 1.52%
629,423
+369,727
+142% +$5.78M
STRO icon
25
Sutro Biopharma
STRO
$339M
$9.8M 1.47%
283,206
-21,129
-7% -$828K
1
2 3

Similar funds

OCM
Opti Capital Management New York $1.64B AUM 0% 1-Year Est. Return
LFS
Lutz Financial Services Omaha, Nebraska $1.64B AUM 15.04% 1-Year Est. Return
TIM
Triodos Investment Management Driebergen-Rijsenburg, Netherlands $1.64B AUM 37.98% 1-Year Est. Return
AAG
Armstrong Advisory Group Needham, Massachusetts $1.64B AUM 19.37% 1-Year Est. Return
MRG
Milestone Resources Group Road Town Tortola, British Virgin Islands $1.64B AUM 2.87% 1-Year Est. Return
EPW
Evolve Private Wealth Los Angeles, California $1.64B AUM
TWM
Tradition Wealth Management Edina, Minnesota $1.64B AUM 26.59% 1-Year Est. Return
MA
MONECO Advisors Fairfield, Connecticut $1.64B AUM 25.43% 1-Year Est. Return

MPM BioImpact's Q3 2024 Portfolio in Review

As of Q3 2024, MPM BioImpact held 54 positions worth $667M, up 3.6% from $644M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

MPM BioImpact's Q3 2024 filing shows 10 new, 20 increased, 7 reduced and 11 closed positions. Its largest new stake was Rocket Pharmaceuticals: 1,066,373 shares worth $19.7M. The largest sale was Alkermes, an estimated $13.4M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • MPM BioImpact's largest Q3 2024 buy was Rocket Pharmaceuticals: 1,066,373 shares worth $19.7M.
  • MPM BioImpact added most to Avidity Biosciences in Q3 2024, an estimated $24.5M increase.
  • MPM BioImpact's biggest Q3 2024 reduction was 89bio, cutting an estimated $6.66M.
  • MPM BioImpact fully exited Alkermes in Q3 2024, selling an estimated $13.4M.
  • MPM BioImpact's ten largest holdings make up 56% of its $667M portfolio in Q3 2024.
  • MPM BioImpact opened 10 new positions and closed 11 in Q3 2024.
  • MPM BioImpact's portfolio value rose 3.6% quarter-over-quarter to $667M.

Based on MPM BioImpact's 13F filing for Q3 2024, filed 13 Nov 2024.